skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 next page
Mostrar Somente
Refinado por: assunto: Type 2 Diabetes remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

Henry, Robert R ; Frias, Juan P ; Walsh, Brandon ; Skare, Sharon ; Hemming, John ; Burns, Colleen ; Bicsak, Thomas A ; Baron, Alain ; Fineman, Mark Samocha-Bonet, Dorit

PloS one, 2018-09, Vol.13 (9), p.e0203946-e0203946 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por
2
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Aroda, Vanita R. ; Capehorn, Matthew S. ; Chaykin, Louis ; Frias, Juan P. ; Lausvig, Nanna L. ; Macura, Stanislava ; Lüdemann, Jörg ; Madsbad, Sten ; Rosenstock, Julio ; Tabak, Omur ; Tadayon, Sayeh ; Bain, Stephen C.

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.303-314

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
3
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial

Frias, Juan P. ; Lee, Martin L. ; Carter, Matthew M. ; Ebel, Emily R. ; Lai, Ren‐Hau ; Rikse, Lars ; Washington, Marc E. ; Sonnenburg, Justin L. ; Damman, Christopher J.

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1203-1212

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
4
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Frías, Juan P ; Davies, Melanie J ; Rosenstock, Julio ; Pérez Manghi, Federico C ; Fernández Landó, Laura ; Bergman, Brandon K ; Liu, Bing ; Cui, Xuewei ; Brown, Katelyn

The New England journal of medicine, 2021-08, Vol.385 (6), p.503-515 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
5
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Frias, Juan P ; Bonora, Enzo ; Nevarez Ruiz, Luis ; Li, Ying G ; Yu, Zhuoxin ; Milicevic, Zvonko ; Malik, Raleigh ; Bethel, M Angelyn ; Cox, David A

Diabetes care, 2021-03, Vol.44 (3), p.765-773 [Periódico revisado por pares]

United States: American Diabetes Association

Texto completo disponível

Citações Citado por
6
Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes
Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes

Frias, Juan P

The Journal of family practice, 2018-06, Vol.67 (6 suppl), p.S25-S34 [Periódico revisado por pares]

United States: Frontline Medical Communications Inc

Texto completo disponível

Citações Citado por
7
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Saxena, Aditi R. ; Frias, Juan P. ; Gorman, Donal N. ; Lopez, Rene N. ; Andrawis, Nabil ; Tsamandouras, Nikolaos ; Birnbaum, Morris J.

Diabetes, obesity & metabolism, 2023-10, Vol.25 (10), p.2805-2814

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
8
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial

McCrimmon, Rory J. ; Catarig, Andrei-Mircea ; Frias, Juan P. ; Lausvig, Nanna L. ; le Roux, Carel W. ; Thielke, Desirée ; Lingvay, Ildiko

Diabetologia, 2020-03, Vol.63 (3), p.473-485 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
9
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
Material Type:
Artigo 		Adicionar ao Meu Espaço

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

McCrimmon, Rory J. ; Cheng, Alice Y.Y. ; Galstyan, Gagik ; Djaballah, Khier ; Li, Xuan ; Coudert, Mathieu ; Frias, Juan P.

Diabetes, obesity & metabolism, 2023-01, Vol.25 (1), p.68-77

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11

Bonora, Enzo ; Frias, Juan P. ; Tinahones, Francisco J. ; Van, Joanna ; Malik, Raleigh E. ; Yu, Zhuoxin ; Mody, Reema ; Bethel, Angelyn ; Kwan, Anita Y. M. ; Cox, David A.

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2242-2250

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (17)

Data de Publicação 

De até
Refinar
  1. Antes de2008  (3)
  2. 2008Até2010  (3)
  3. 2011Até2016  (3)
  4. 2017Até2019  (10)
  5. Após 2019  (16)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.